Preclinical evaluation of the safety and pathogenicity of a live attenuated recombinant influenza A/H7N9 seed strain and corresponding MF59-adjuvanted split vaccine
Metrics: PDF 1651 views | HTML 2559 views | ?
Huilin Ou1,*, Wei Yao2,*, Nanping Wu1, Frederick X.C. Wang3, Tianhao Weng1, Chengcong Han2, Xiangyun Lu1, Dongshan Yu1, Haibo Wu1, Linfang Cheng1, Honglin Chen4, Hangping Yao1, Lanjuan Li1
1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
2Department of Pre-clinical Research and Development, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., Hangzhou, China
3Department of Bioengineering, Erik Jonsson School of Engineering and Computer Science, The University of Texas at Dallas, Texas, USA
4State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong, China
*These authors have contributed equally to this work
Lanjuan Li, email: [email protected]
Hangping Yao, email: [email protected]
Keywords: H7N9, safety and toxicity, H7N9 vaccine, H7N9 seed strain
Received: July 07, 2016 Accepted: October 12, 2016 Published: October 19, 2016
Developing a safe and effective H7N9 influenza vaccine was initiated in early spring 2013, following human infections with a novel avian influenza A (H7N9) virus. In this study, a candidate H7N9 vaccine seed strain is produced using reverse genetics, with HA and NA derived from a human H7N9 virus and the remaining genes from the PR8 backbone virus which grows well in eggs. We verified that the virulence and transmissibility of the recombinant H7N9 vaccine seed strain were decreased as compared to wild-type H7N9 virus, to levels comparable with PR8. Using the seed virus, we produced a monovalent split influenza A (H7N9) MF59-adjuvanted vaccine that was immunogenic in mice. Our H7N9 vaccine is selected for clinical investigation and potential human use. To assess the safety of our H7N9 vaccine, we performed acute toxicity, repeated dose toxicity and active systemic anaphylaxis tests. Our results showed that, under the conditions used in this study, the NOEAL (no obvious adverse effect level) was 30 μg/0.5 mL.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.